Welch & Forbes’s AbbVie ABBV Stock Holding History

Welch & Forbes’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87.1M	Buy	345,978 +2,363	+0.7%	+$508K	1.06%	27
2026 Q1	$74.7M	Sell	343,615 -2,332	-0.7%	-$517K	0.97%	29
2025 Q4	$79M	Sell	345,947 -2,424	-0.7%	-$552K	0.96%	32
2025 Q3	$80.7M	Sell	348,371 -1,539	-0.4%	-$313K	0.97%	33
2025 Q2	$65M	Sell	349,910 -4,714	-1%	-$876K	0.81%	38
2025 Q1	$74.3M	Sell	354,624 -8,924	-2%	-$1.73M	0.97%	31
2024 Q4	$64.6M	Sell	363,548 -1,021	-0.3%	-$188K	0.83%	39
2024 Q3	$72M	Sell	364,569 -6,283	-2%	-$1.17M	0.92%	36
2024 Q2	$62.4M	Sell	370,852 -924	-0.2%	-$153K	0.83%	38
2024 Q1	$67.7M	Sell	371,776 -10,200	-3%	-$1.76M	0.93%	35
2023 Q4	$59.2M	Sell	381,976 -13,090	-3%	-$1.91M	0.89%	35
2023 Q3	$58.9M	Sell	395,066 -7,243	-2%	-$1.06M	0.97%	36
2023 Q2	$54.2M	Sell	402,309 -4,992	-1%	-$732K	0.86%	38
2023 Q1	$64.9M	Sell	407,301 -8,163	-2%	-$1.25M	1.1%	28
2022 Q4	$67.1M	Buy	415,464 +1,843	+0.4%	+$283K	1.2%	25
2022 Q3	$55.5M	Sell	413,621 -1,399	-0.3%	-$201K	1.08%	30
2022 Q2	$63.6M	Sell	415,020 -7,638	-2%	-$1.17M	1.16%	27
2022 Q1	$68.5M	Buy	422,658 +14,679	+4%	+$2.13M	1.08%	28
2021 Q4	$55.2M	Sell	407,979 -2,705	-0.7%	-$320K	0.83%	37
2021 Q3	$44.3M	Buy	410,684 +2,137	+0.5%	+$244K	0.74%	39
2021 Q2	$46M	Buy	408,547 +2,538	+0.6%	+$286K	0.78%	37
2021 Q1	$43.9M	Buy	406,009 +7,634	+2%	+$817K	0.81%	39
2020 Q4	$42.7M	Sell	398,375 -4,718	-1%	-$453K	0.84%	37
2020 Q3	$35.3M	Buy	403,093 +3,550	+0.9%	+$334K	0.76%	40
2020 Q2	$39.2M	Sell	399,543 -12,485	-3%	-$1.1M	0.92%	33
2020 Q1	$31.4M	Sell	412,028 -6,854	-2%	-$584K	0.88%	36
2019 Q4	$37.1M	Sell	418,882 -3,583	-0.8%	-$297K	0.83%	39
2019 Q3	$32M	Sell	422,465 -16,183	-4%	-$1.11M	0.76%	42
2019 Q2	$31.9M	Sell	438,648 -18,095	-4%	-$1.42M	0.78%	43
2019 Q1	$36.8M	Sell	456,743 -22	-0%	-$1.8K	0.92%	35
2018 Q4	$42.1M	Sell	456,765 -4,744	-1%	-$417K	1.19%	24
2018 Q3	$43.6M	Buy	461,509 +1,299	+0.3%	+$123K	1.04%	29
2018 Q2	$42.6M	Sell	460,210 -4,500	-1%	-$439K	1.1%	28
2018 Q1	$44M	Buy	+464,710	New	+$51M	1.13%	25
2017 Q4	–	Sell	-483,973	Closed	-$43M	–	339
2017 Q3	$43M	Buy	483,973 +555	+0.1%	+$42.2K	1.13%	25
2017 Q2	$35.1M	Sell	483,418 -15,521	-3%	-$1.04M	0.98%	30
2017 Q1	$32.5M	Sell	498,939 -1,260	-0.3%	-$79.2K	0.93%	33
2016 Q4	$31.3M	Buy	+500,199	New	+$30.5M	0.94%	33
2016 Q3	–	Sell	-505,801	Closed	-$31.3M	–	305
2016 Q2	$31.3M	Sell	505,801 -3,085	-0.6%	-$188K	0.95%	32
2016 Q1	$29.1M	Sell	508,886 -6,713	-1%	-$374K	0.91%	33
2015 Q4	$30.5M	Sell	515,599 -4,568	-0.9%	-$263K	0.98%	30
2015 Q3	$28.3M	Sell	520,167 -9,634	-2%	-$627K	0.94%	35
2015 Q2	$35.6M	Sell	529,801 -10,845	-2%	-$708K	1.11%	30
2015 Q1	$31.6M	Sell	540,646 -17,619	-3%	-$1.06M	0.95%	35
2014 Q4	$36.5M	Sell	558,265 -7,650	-1%	-$482K	1.07%	31
2014 Q3	$32.7M	Buy	565,915 +6,861	+1%	+$381K	1%	37
2014 Q2	$31.6M	Sell	559,054 -2,412	-0.4%	-$127K	1%	35
2014 Q1	$28.9M	Sell	561,466 -13,480	-2%	-$681K	0.91%	40
2013 Q4	$30.4M	Sell	574,946 -9,183	-2%	-$451K	0.96%	37
2013 Q3	$26.1M	Sell	584,129 -13,247	-2%	-$587K	0.88%	40
2013 Q2	$24.7M	Buy	+597,376	New	+$26.1M	0.88%	42

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Welch & Forbes's ABBV Position: Q2 2026 in Review

Welch & Forbes increased its AbbVie (ABBV) stake by 0.69% in Q2 2026, buying an estimated $508K and bringing the position to 345,978 shares worth $87.1M. The position accounts for 1.06% of the portfolio, ranked #27.

Welch & Forbes first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Welch & Forbes held 345,978 shares of AbbVie worth $87.1M as of Q2 2026.
Welch & Forbes bought 2,363 AbbVie shares in Q2 2026, an estimated $508K.
AbbVie made up 1.06% of Welch & Forbes's portfolio in Q2 2026, its #27 holding.
Welch & Forbes first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Welch & Forbes's 13F filing for Q2 2026, filed 30 Jul 2026.